N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Phase 2 N=52 Combination Vaccination Before HIV Treatment Interruption
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 2 N=43 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
Yellow Fever
Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 4 N=86 Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 42; 19; 25 Participants
Phase 2 N=127 Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Breast Cancer · Lung Cancer · Prostate Cancer
Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
Phase 4 N=34 Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Influenza
Primary: Number of Subjects Shedding Vaccine Virus of Each Subtype by PCR — 1; 6; 9; 1 participants
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Phase 4 N=104 Body and Social Behavior
Psychology, Social · Inflammation · Defeat, Social
Primary: IL-6 Levels 24 Hours After Vaccine — 0.40; 0.23 log pg/mL — p=<0.001
Phase 4 N=78 The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
N/A N=87,665 From Innovation to Solutions: Childhood Influenza Vaccination Planning
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
N/A N=11,834 The Impact of Vaccination on Severity of Illness in COVID-19
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
Phase 4 N=66 Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Covid19
Primary: Ratio of 48-Week to Baseline Neutralizing Antibody (NAb) Levels — 0.3722; 0.5883; 0.2088; 0.3073 ratio of geometric mean responses
N/A N=50 Effect of Obesity on Immune Response to Pneumovax 23
Obesity
Primary: Anti-pneumococcal Antibodies Between the Groups — 34.1; 19.8 titer
N/A N=88 Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
Phase 2 N=79 Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
N/A N=15 γ-irradiated BCG to Train Innate Immunity
Innate Immune Response
Primary: Cytokine Production Measured by ELISA Compared to Baseline — 1.2 ratio
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Phase 4 N=219 Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
Chronic Obstructive Pulmonary Disease · Asthma · Pneumococcal Infections
Primary: Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation. — 3; 5; 1; 0 Participants — p=<0.05